

# Amir Bloor Joins Covalon's Board of Directors

MISSISSAUGA, Ontario--(BUSINESS WIRE)--April 27, 2020--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is delighted to announce that Mr. Amir Bloor has joined its Board of Directors.

Brian Pedlar, Covalon's CEO, said, "I am delighted that Amir Bloor has agreed to join Covalon's Board. Amir has been a significant long-time Covalon shareholder and he has much to offer us in terms of advice and counsel."

Amir Bloor said, "I have been an avid follower and investor in Covalon for several years. Covalon has several impressive technology platforms that are still in their early stages of monetization. I believe that Covalon has great potential to achieve much more both in the lucrative American and international markets. I look forward to assisting wherever I can."

Mr. Bloor is the President of Caspian Equity Partners, Inc. of Vancouver, British Columbia, a private investment firm he founded in 2012. He has specialized in helping entrepreneurs accelerate growth and optimize performance, while propelling long-term profitability and value.

Prior to founding Caspian Equity Partners, Inc., Mr. Bloor held various positions in the Mergers & Acquisitions and Diversified Investment Banking groups of TD Securities, Inc. where he advised Boards and Executive Teams of mid-market and large-cap companies on numerous strategic review mandates, initial public offerings, mergers, acquisitions, divestitures, corporate restructures, leveraged buyouts, and takeover defenses.

Mr. Bloor has a Bachelor of Commerce degree in Finance (with Honours) from the University of British Columbia. Mr. Bloor is a Chartered Financial Analyst from the CFA Institute.

Mr. Bloor's appointment to Covalon's Board of Directors is subject to TSX approval.

## About Covalon

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at [www.covalon.com](http://www.covalon.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.*

## **Contacts**

Brian Pedlar, CEO, Covalon Technologies Ltd.

Email: [bpedlar@covalon.com](mailto:bpedlar@covalon.com)

Phone: 905.568.8400 x 233

Toll free: 1.877.711.6055

Web site: [www.covalon.com](http://www.covalon.com)

Twitter: [@covalon](https://twitter.com/covalon)